Antares Pharma Inc.   Report issue

For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Minneapolis MN United States (1979)
Status: Acquired by Halozyme Therapeutics (2022)

Organization Overview

First Clinical Trial
2009
NCT00909181
First Marketed Drug
2013
naltrexone (revia)
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Antares Pharma Inc. | ANTARES PHARMA INC

Active Ingredients

Marketed Drugs (3)

naltrexone (revia) (2013)

sumatriptan (zecuity) (2015)

testosterone (delatestryl) (2018)

Drugs in Phase 4 Trials (1)

testosterone (delatestryl) (6 trials)

Drugs in Phase 3 Trials (1)

oxybutynin (ditropan) (1 trial)

Drugs in Phase 2 Trials (2)

naltrexone (revia) (2 trials)

urea (1 trial)

Drugs in Phase 1 Trials (1)

abiraterone (zytiga) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Arthritis (Phase 2)

Arthritis, Rheumatoid (Phase 2)

Enuresis (Phase 3)

Hypogonadism (Phase 3)

Urinary Incontinence (Phase 3)

Urinary Incontinence, Urge (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 10
  • # of Trial APIs: 5